Academia

A review of current molecular and electrophysiological biomarkers in spinal muscular atrophy (SMA) concluded that more exploration is necessary to find noninvasive, yet accurate, measures of disease progression and therapy response.

The benefit of real-world evidence is that it provides more data on subpopulations and diverse populations, said Christina Barrington, vice president of pharmacy programs at Priority Health.

There are several reasons as to why precision therapeutics have not taken off for chronic obstructive pulmonary disease (COPD) in the same way that they have for other diseases, said Don Sin, MD, FRCP, MPH, a professor of respiratory medicine at the University of British Columbia and head of the Centre of Heart Lung Innovation, St. Paul’s Hospital.

Dosing from pivotal phase 3 trials of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) is not optimal for real-world patients who experience different efficacy and adverse events (AEs).

Increasing knowledge of mutations and signaling proteins in diffuse large B-cell lymphoma (DLBCL) offer prognostic and therapeutic advantages, according to a review of recent findings.

In the opening sessions at the Patient-Centered Oncology Care® conference, held September 23-24 both virtually and in Nashville, Tennessee, speakers focused on addressing disparities by getting involved and engaged with the community.

At the 10th anniversary meeting of Patient-Centered Oncology Care®, sessions will cover reducing disparities in cancer care, bringing clinical trials closer to the community, and expanding the scope of what the term "precision medicine" means in cancer care.

The fallout from COVID-19 has spotlighted the limitations of US mental health care, prompting the question if alternative treatments—like psychedelics—could help address current and impending crises.

Investigators examined medical records spanning 3 decades to look at the effect of poorly differentiated tumor size on outcomes in survival in hepatocellular carcinoma (HCC).

Increasing air pollution and climate change have an impact on respiratory health and mortality, explained speakers in 2 sessions on the environment and respiratory diseases at the European Respiratory Society International Congress 2021.

Health care and research need to do a better job of taking into account sex and gender differences that can affect disease, healthy behaviors, and care delivery, according to speakers at the European Respiratory Society International Congress 2021.

The 5-year update could help solidify the role of sodium glucose co-transporter 2 (SGLT2) inhibitors in treating heart failure, years after the first evidence of their effectiveness emerged.

Researchers conducted a literature survey about chronic cough symptoms to create a patient-reported outcome measurement (PROM) tool in order to measure cough severity.

Treatment-related modifications have resulted in improved long-term outcomes for all adolescent and young adult (AYA) survivors of Hodgkin lymphoma, but new research highlights that racial, ethnic, and socioeconomic status disparities persist in the long term.

Patients may find a placebo effect beneficial, but it causes issues in a clinical trial and makes it difficult to understand the efficacy of a pharmacological agent, said Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.

Dynamic measurable residual disease (MRD) can be used to optimize postremission treatment for young patients with acute myeloid leukemia (AML).

A new treatment using human immune cells can prevent infections in patients with leukemia who have a weakened immune system due to treatment for their disease.

The nationwide, population-based study analyzed data on over 1900 patients with primary myelofibrosis (pMF), comparing rates of survival from 2001-2010 with 2011-2018.

In a recent review, researchers describe what is currently known about allogenic hemopoietic stem cell transplant (HSCT) for myelofibrosis.

Posters presented at the European Hematology Association 2021 Virtual Congress evaluated acute myeloid leukemia (AML) in elderly patients.

A long-term Swedish study found that nonalcoholic fatty liver disease (NALFD) significantly increased mortality in children and young adults, particularly due to cancer, cardiometabolic disease, and liver disease.

Minimal residual disease, overall response rate, complete response rate, and stringent complete response may be useful as surrogate end points to estimate progression-free survival (PFS) benefit for patients with newly diagnosed multiple myeloma.

OTC cough medicines may have some temporary benefit, but they don't penetrate the nerves in the airways, which are believed to be the mechanism behind refractory chronic cough, says Jacky Smith, MB, ChB, FRCP, PhD, professor of respiratory medicine at the University of Manchester and an honorary consultant at Manchester University NHS Foundation Trust.

New antitussive trials are challenged by large placebo effects and the risk of the trial being unblinded due to adverse effects, explained Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.

The latest phase 2 MAGNOLIA results continue to show strong efficacy and tolerability for the Bruton tyrosine kinase inhibitor in marginal zone lymphoma.

Updated guidelines for adults and children highlight confusion over the name of the condition and the need for greater evidence.

The placebo effect is a major problem in cough trials and can make it impossible to tell the true pharmacological effect of the medicine being studied, said Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.

An interim analysis of the phase 3 ALPINE study demonstrated that zanubrutinib has a superior response rate, improved progressive-free survival, and lower rate of atrial fibrillation/flutter compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/ small lymphocytic leukemia (CLL/SLL).

Desensitizing the cough reflex and new technologies based on artificial intelligence are some of the oral abstracts that Jacky Smith, MB, ChB, FRCP, PhD, professor of respiratory medicine at the University of Manchester and an honorary consultant at Manchester University NHS Foundation Trust, who chairs that session, is looking forward to at the American Cough Conference.

The populations represented in randomized controlled trials often do not match the populations being treated in the real world due to eligibility criteria, which can be challenging when translating those results to real-world decisions, explained speakers during a session at the European Hematology Association 2021 Virtual Congress.